Literature DB >> 21916830

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.

Ranjana H Advani, Fangxin Hong, Sandra J Horning, Brad S Kahl, Judith Manola, Lode J Swinnen, Thomas M Habermann, Kristen Ganjoo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21916830      PMCID： PMC3919492          DOI： 10.3109/10428194.2011.623256

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

Review 1.  Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.

Authors:  I Zachary
Journal:  Am J Physiol Cell Physiol       Date:  2001-06       Impact factor: 4.249

2.  Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?

Authors:  Nitin Verma; Sandra M Swain
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

3.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

4.  Aggressive peripheral T-cell lymphomas (specified and unspecified types).

Authors:  Kerry J Savage
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

5.  Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Authors:  Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 6.  Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.

Authors:  Vishal Ranpura; Bhargava Pulipati; David Chu; Xiaolei Zhu; Shenhong Wu
Journal:  Am J Hypertens       Date:  2010-02-25       Impact factor: 2.689

7.  A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  K D Miller; A O'Neill; E A Perez; A D Seidman; G W Sledge
Journal:  Ann Oncol       Date:  2011-08-04       Impact factor: 32.976

8.  Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

Authors:  David R D'Adamo; Sibyl E Anderson; Karen Albritton; Jennifer Yamada; Elyn Riedel; Kelly Scheu; Gary K Schwartz; Helen Chen; Robert G Maki
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

9.  A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function.

Authors:  F J Giordano; H P Gerber; S P Williams; N VanBruggen; S Bunting; P Ruiz-Lozano; Y Gu; A K Nath; Y Huang; R Hickey; N Dalton; K L Peterson; J Ross; K R Chien; N Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

10.  Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.

Authors:  Kristen N Ganjoo; Caroline S An; Michael J Robertson; Leo I Gordon; Joy A Sen; Jill Weisenbach; Shuli Li; Edie A Weller; Attilio Orazi; Sandra J Horning
Journal:  Leuk Lymphoma       Date:  2006-06
View more
  7 in total

1.  A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Authors:  Ranjana H Advani; Stephen M Ansell; Mary J Lechowicz; Anne W Beaven; Fausto Loberiza; Kenneth R Carson; Andrew M Evens; Francine Foss; Steven Horwitz; Barbara Pro; Lauren C Pinter-Brown; Sonali M Smith; Andrei R Shustov; Kerry J Savage; Julie M Vose
Journal:  Br J Haematol       Date:  2015-12-02       Impact factor: 6.998

Review 2.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.

Authors:  Nicole S Klee; Cameron G McCarthy; Patricia Martinez-Quinones; R Clinton Webb
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-09-15

3.  Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.

Authors:  Haruka Chino; Yosuke Amano; Yasuhiro Yamauchi; Jun Matsuda; Norihiko Takeda; Goh Tanaka; Daiya Takai; Takahide Nagase
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 4.  From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Authors:  Andrew M Intlekofer; Anas Younes
Journal:  Int J Hematol       Date:  2014-02-08       Impact factor: 2.490

5.  Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).

Authors:  Kristen Ganjoo; Fangxin Hong; Sandra J Horning; Randy D Gascoyne; Yasodha Natkunam; Lode J Swinnen; Thomas M Habermann; Brad S Kahl; Ranjana H Advani
Journal:  Leuk Lymphoma       Date:  2013-07-29

6.  CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.

Authors:  Young Wha Koh; Chan-Sik Park; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

7.  The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH.

Authors:  Jin-Hua Liang; Luo Lu; Hua-Yuan Zhu; Wang Li; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Res Treat       Date:  2018-04-02       Impact factor: 4.679
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.